Latest news with #EAS)Congress
Yahoo
07-05-2025
- Health
- Yahoo
Marea Therapeutics Presents Positive Data from Phase 2a Clinical Trial of MAR001, Being Developed for Cardiovascular Disease, in Late-Breaking Oral Session at the 93rd EAS Congress
MAR001, a first-in-class monoclonal antibody targeting ANGPTL4, demonstrated approximately 53% placebo-adjusted mean reduction in remnant cholesterol and placebo-adjusted mean reduction in triglycerides at 12 weeks Approximately 65% placebo-adjusted mean reduction in remnant cholesterol and triglycerides in participants with greater triglyceride elevation at baseline (≥200 mg/dl) MAR001 was generally well tolerated; Phase 2b study expected to initiate in second quarter of 2025 Second oral presentation at EAS describes association of remnant cholesterol levels with major cardiovascular events in patients with atherosclerotic cardiovascular disease, underscoring potential of MAR001 to become an important new therapeutic option SOUTH SAN FRANCISCO, Calif., May 07, 2025--(BUSINESS WIRE)--Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today presented positive data from a Phase 2a clinical trial of MAR001 in a late-breaking oral session at the 93rd European Atherosclerosis Society (EAS) Congress being held May 4-7, 2025 in Glasgow, UK. MAR001 is a first-in-class monoclonal antibody that targets ANGPTL4, a protein that is highly expressed in adipose tissue. "We are very excited by these data from our Phase 2a study, which demonstrate the strong potential of MAR001 to address the most important unaddressed lipid and metabolic drivers of atherosclerotic cardiovascular disease in high-risk patients," said Josh Lehrer, M.D., FACC, chief executive officer of Marea. "We look forward to advancing MAR001 into Phase 2b development for treating residual cardiovascular risk in patients who remain at highest risk despite aggressive standard of care therapies." "Atherosclerotic cardiovascular disease patients with elevated remnant cholesterol remain at an increased risk for major adverse cardiovascular events despite best available standard of care therapies," said Ethan Weiss, M.D., chief scientific officer of Marea. "These data clearly validate the ability of MAR001 to significantly lower remnant cholesterol and triglycerides by inhibiting ANGPTL4, supporting genetic findings and expected translation to substantial cardiovascular disease risk reduction. We believe MAR001 has the potential to become an important new therapeutic option for patients." Presentation Highlights:
Business Wire
23-04-2025
- Health
- Business Wire
Scribe Therapeutics to Unveil Latest Preclinical Data on Proprietary CRISPR Epigenetic Silencing Technology for LDL-C Lowering at the 2025 EAS Congress
ALAMEDA, Calif.--(BUSINESS WIRE)--Scribe Therapeutics Inc. (Scribe), a genetic medicines company unlocking the potential of CRISPR to transform human health, today announced a late-breaking oral presentation at the 93rd European Atherosclerosis Society (EAS) Congress taking place between May 4-7, 2025, at the Scottish Event Campus in Glasgow, United Kingdom. Aarif Khakoo, M.D., M.B.A., Chief Scientific Officer and Head of Research and Development at Scribe, will present the company's latest data on the application of its cutting-edge CRISPR-based epigenetic silencer at therapeutically relevant doses for the potent, durable, and safe reduction of low-density lipoprotein cholesterol (LDL-C) in non-human primates. Scribe's iterative engineering and improvement of its epigenetic silencing technology, called the Epigenetic Long-Term X-Repressor (ELXR), is guided by its CRISPR by Design™ approach to create best-in-class in vivo genetic medicines that can transform the standard of care for broad patient populations, starting with cardiometabolic disease. The presentation details are listed below and in the EAS Congress program. Title: Potent, Durable, and Safe LDLc Reduction in Non-Human Primates with a Novel CRISPR-based Epigenetic Silencer at Therapeutically Relevant Doses Session title: Late Breaker Session: Basic Science Date: Time: 4:00 - 4:15 p.m. BST Location: William Harvey Hall About Scribe Therapeutics Scribe Therapeutics is revolutionizing medicine by developing optimized in vivo CRISPR-based genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases, starting with cardiometabolic disease. The company is on a mission to build the first CRISPR-based therapeutics that are effective and safe enough to transform everyone's lifetime risk for disease. Scribe's CRISPR by Design™ approach engineers bacterial immune systems into a premier suite of genome and epigenome editing tools built for unique molecular advantages in activity, specificity, and deliverability, enabling the creation of therapies with a broader therapeutic window and safe for use as a preventative treatment. The company's lead candidate, STX-1150, is a novel liver-targeted therapy designed to epigenetically silence the PCSK9 gene, resulting in significant and durable reduction of LDL-C levels. To broaden and accelerate the impact of its engineered CRISPR technologies for patients, Scribe has formed strategic collaborations with world-leading pharmaceutical companies including Sanofi and Eli Lilly. Co-founded by Nobel Prize winner Jennifer Doudna and backed by leading life sciences investors, Scribe is engineering the future of genetic medicine. To learn more, visit
Yahoo
23-04-2025
- Health
- Yahoo
Scribe Therapeutics to Unveil Latest Preclinical Data on Proprietary CRISPR Epigenetic Silencing Technology for LDL-C Lowering at the 2025 EAS Congress
Late-breaking presentation will report on Scribe's advances developing a novel CRISPR-based epigenetic silencer to potently, durably, and safely reduce low-density lipoprotein cholesterol in non-human primates at therapeutically relevant doses ALAMEDA, Calif., April 23, 2025--(BUSINESS WIRE)--Scribe Therapeutics Inc. (Scribe), a genetic medicines company unlocking the potential of CRISPR to transform human health, today announced a late-breaking oral presentation at the 93rd European Atherosclerosis Society (EAS) Congress taking place between May 4-7, 2025, at the Scottish Event Campus in Glasgow, United Kingdom. Aarif Khakoo, M.D., M.B.A., Chief Scientific Officer and Head of Research and Development at Scribe, will present the company's latest data on the application of its cutting-edge CRISPR-based epigenetic silencer at therapeutically relevant doses for the potent, durable, and safe reduction of low-density lipoprotein cholesterol (LDL-C) in non-human primates. Scribe's iterative engineering and improvement of its epigenetic silencing technology, called the Epigenetic Long-Term X-Repressor (ELXR), is guided by its CRISPR by Design™ approach to create best-in-class in vivo genetic medicines that can transform the standard of care for broad patient populations, starting with cardiometabolic disease. The presentation details are listed below and in the EAS Congress program. Title: Potent, Durable, and Safe LDLc Reduction in Non-Human Primates with a Novel CRISPR-based Epigenetic Silencer at Therapeutically Relevant DosesSession title: Late Breaker Session: Basic ScienceDate: Monday, May 5, 2025Time: 4:00 - 4:15 p.m. BSTLocation: William Harvey Hall About Scribe Therapeutics Scribe Therapeutics is revolutionizing medicine by developing optimized in vivo CRISPR-based genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases, starting with cardiometabolic disease. The company is on a mission to build the first CRISPR-based therapeutics that are effective and safe enough to transform everyone's lifetime risk for disease. Scribe's CRISPR by Design™ approach engineers bacterial immune systems into a premier suite of genome and epigenome editing tools built for unique molecular advantages in activity, specificity, and deliverability, enabling the creation of therapies with a broader therapeutic window and safe for use as a preventative treatment. The company's lead candidate, STX-1150, is a novel liver-targeted therapy designed to epigenetically silence the PCSK9 gene, resulting in significant and durable reduction of LDL-C levels. To broaden and accelerate the impact of its engineered CRISPR technologies for patients, Scribe has formed strategic collaborations with world-leading pharmaceutical companies including Sanofi and Eli Lilly. Co-founded by Nobel Prize winner Jennifer Doudna and backed by leading life sciences investors, Scribe is engineering the future of genetic medicine. To learn more, visit View source version on Contacts Media Contact: Thermal for Scribe Therapeuticsmedia@
